TOKYO -- Daiichi Sankyo plans to begin Phase 3 clinical trials for its coronavirus vaccine this autumn with the aim of bringing it to the public in 2022, finally pushing forward Japan's effort to locally develop COVID-19 shots.
A few other Japanese drugmakers are also making progress in vaccine development, including Shionogi, which says it would be able to supply enough doses for 60 million people a year if a reduced dose proves to be as effective as the previously proposed amount.
